{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:29:40Z","timestamp":1773905380728,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-024-04717-7","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T02:28:51Z","timestamp":1732674531000},"page":"2710-2719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prognostic value of central gland volume on MRI for biochemical recurrence after prostate radiotherapy"],"prefix":"10.1007","volume":"50","author":[{"given":"Joseph","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Salari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirisha","family":"Nandalur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayf","family":"Al-Katib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiran","family":"Nandalur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"4717_CR1","unstructured":"National Cancer Institute. Cancer stat facts: prostate cancer. Available at: (https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html). Published 2023. Accessed March 16, 2024."},{"key":"4717_CR2","first-page":"2351","volume":"11","author":"J Wang","year":"2021","unstructured":"Wang J, Xia HH, Zhang Y, et al. Trends in treatments for prostate cancer in the united states, 2010\u20132015. Am J Cancer Res 2021;11:2351\u20132368.","journal-title":"Am J Cancer Res"},{"key":"4717_CR3","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.eururo.2008.11.011","volume":"55","author":"A Alcaraz","year":"2009","unstructured":"Alcaraz A, Hammerer P, Tubaro A, et al. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol 2009;55:864\u201373. doi:https:\/\/doi.org\/10.1016\/j.eururo.2008.11.011","journal-title":"Eur Urol"},{"key":"4717_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrurol.2012.192","volume":"10","author":"DD \u00d8rsted","year":"2013","unstructured":"\u00d8rsted DD, Bojesen SE. The link between benign prostatic hyperplasia and prostate cancer. Nat Rev Urol 2013;10:49\u201354. doi:https:\/\/doi.org\/10.1038\/nrurol.2012.192","journal-title":"Nat Rev Urol"},{"key":"4717_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.urology.2014.04.006","volume":"84","author":"SK Hong","year":"2014","unstructured":"Hong SK, Poon BY, Sjoberg DD, et al. Prostate size and adverse pathologic features in men undergoing radical prostatectomy. Urology 2014;84:153\u20137. doi:https:\/\/doi.org\/10.1016\/j.urology.2014.04.006","journal-title":"Urology"},{"key":"4717_CR6","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.1200\/JCO.2005.05.525","volume":"23","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Isaacs WB, Platz EA, et al. Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: A search database study. J Clin Oncol 2005;23:7546\u201354. doi:https:\/\/doi.org\/10.1200\/JCO.2005.05.525","journal-title":"J Clin Oncol"},{"key":"4717_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/pros.24207","volume":"81","author":"KR Nandalur","year":"2021","unstructured":"Nandalur KR, Colvin R, Walker D, et al. Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics. Prostate 2021;81:1097\u20131104. doi:https:\/\/doi.org\/10.1002\/pros.24207","journal-title":"Prostate"},{"key":"4717_CR8","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.plrev.2023.01.017","volume":"44","author":"B Blanco","year":"2023","unstructured":"Blanco B, Gomez H, Melchor J, et al. Mechanotransduction in tumor dynamics modeling. Phys Life Rev 2023;44:279\u2013301. doi:https:\/\/doi.org\/10.1016\/j.plrev.2023.01.017","journal-title":"Phys Life Rev"},{"key":"4717_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1073\/pnas.1815735116","volume":"116","author":"G Lorenzo","year":"2019","unstructured":"Lorenzo G, Hughes TJR, Dominguez-Frojan P, et al. Computer simulations suggest that prostate enlargement due to benign prostatic hyperplasia mechanically impedes prostate cancer growth. Proc Natl Acad Sci U S A 2019;116:1152\u20131161. doi:https:\/\/doi.org\/10.1073\/pnas.1815735116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4717_CR10","doi-asserted-by":"publisher","first-page":"e104717","DOI":"10.1371\/journal.pone.0104717","volume":"9","author":"C Voutouri","year":"2014","unstructured":"Voutouri C, Mpekris F, Papageorgis P, et al. Role of constitutive behavior and tumor-host mechanical interactions in the state of stress and growth of solid tumors. PLoS One 2014;9:e104717. doi:https:\/\/doi.org\/10.1371\/journal.pone.0104717","journal-title":"PLoS One"},{"key":"4717_CR11","doi-asserted-by":"publisher","first-page":"3833","DOI":"10.1158\/0008-5472.CAN-12-4521","volume":"73","author":"T Stylianopoulos","year":"2013","unstructured":"Stylianopoulos T, Martin JD, Snuderl M, et al. Coevolution of solid stress and interstitial fluid pressure in tumors during progression: Implications for vascular collapse. Cancer Res2013;73:3833\u201341. doi:https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-4521","journal-title":"Cancer Res"},{"key":"4717_CR12","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 4.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed June 26, 2024."},{"key":"4717_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.clinimag.2021.09.003","volume":"80","author":"R Colvin","year":"2021","unstructured":"Colvin R, Walker D, Hafron J, et al. Which measurement method should be used for prostate volume for pi-rads? A comparison of ellipsoid and segmentation methods. Clin Imaging2021;80:454\u2013458. doi:https:\/\/doi.org\/10.1016\/j.clinimag.2021.09.003","journal-title":"Clin Imaging"},{"key":"4717_CR14","doi-asserted-by":"publisher","unstructured":"Nandalur KR, Walker D, Ye H, et al. Impact of the bladder detrusor muscular ring on lower urinary tract symptoms due to benign prostatic hyperplasia: A quantitative mri analysis. Prostate2023;83:259\u2013267. doi:https:\/\/doi.org\/10.1002\/pros.24457","DOI":"10.1002\/pros.24457"},{"key":"4717_CR15","doi-asserted-by":"publisher","first-page":"e220096","DOI":"10.1148\/rg.220096","volume":"43","author":"EA Han","year":"2023","unstructured":"Han EA, Nandalur KR, Morgan MA, et al. Mri of benign prostatic hyperplasia: Important pre- and posttherapeutic considerations. Radiographics 2023;43:e220096. doi:https:\/\/doi.org\/10.1148\/rg.220096","journal-title":"Radiographics"},{"key":"4717_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM, et al. Variability of the positive predictive value of PI-RADS for prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology 2020; 296:76\u201384. doi:https:\/\/doi.org\/10.1148\/radiol.2020190646","journal-title":"Radiology"},{"key":"4717_CR17","doi-asserted-by":"publisher","first-page":"e180039-e180039","DOI":"10.1001\/jamaoncol.2018.0039","volume":"4","author":"JM Michalski","year":"2018","unstructured":"Michalski JM, Moughan J, Purdy J, et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial. JAMA oncology 2018; 4:e180039-e180039. doi:https:\/\/doi.org\/10.1001\/jamaoncol.2018.0039","journal-title":"JAMA oncology"},{"key":"4717_CR18","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. Journal of Clinical Oncology 2016; 34:2325\u20132332. doi:https:\/\/doi.org\/10.1200\/JCO.2016.67.0448","journal-title":"Journal of Clinical Oncology"},{"key":"4717_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.ijrobp.2015.10.011","volume":"94","author":"MS Jawad","year":"2016","unstructured":"Jawad MS, Dilworth JT, Gustafson GS, et al. Outcomes associated with 3 treatment schedules of high-dose-rate brachytherapy monotherapy for favorable-risk prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2016; 94:657\u2013666. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2015.10.011","journal-title":"International Journal of Radiation Oncology* Biology* Physics"},{"key":"4717_CR20","first-page":"e2-e3","volume":"117","author":"N Van As","year":"2023","unstructured":"Van As N, Tree A, Patel J, et al. 5-year outcomes from PACE B: An international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer. International Journal of Radiation Oncology* Biology* Physics 2023; 117:e2-e3.","journal-title":"International Journal of Radiation Oncology* Biology* Physics"},{"key":"4717_CR21","doi-asserted-by":"publisher","unstructured":"Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the rtog-astro phoenix consensus conference. Int J Radiat Oncol Biol Phys 2006;65:965\u2013\u200974. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2006.04.029","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"4717_CR22","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1002\/sim.6607","volume":"34","author":"PC Austin","year":"2015","unstructured":"Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (iptw) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661\u201379. doi:https:\/\/doi.org\/10.1002\/sim.6607","journal-title":"Stat Med"},{"key":"4717_CR23","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/EDE.0000000000000053","volume":"25","author":"AI Naimi","year":"2014","unstructured":"Naimi AI, Moodie EE, Auger N, et al. Constructing inverse probability weights for continuous exposures: A comparison of methods. Epidemiology 2014;25:292\u20139. doi:https:\/\/doi.org\/10.1097\/EDE.0000000000000053","journal-title":"Epidemiology"},{"key":"4717_CR24","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/s0090-4295(98)00574-3","volume":"53","author":"ME Chen","year":"1999","unstructured":"Chen ME, Troncoso P, Johnston D, et al. Prostate cancer detection: Relationship to prostate size. Urology 1999;53:764\u20138. doi:https:\/\/doi.org\/10.1016\/s0090-4295(98)00574-3.","journal-title":"Urology"},{"key":"4717_CR25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.urology.2006.09.041","volume":"69","author":"R Al-Azab","year":"2007","unstructured":"Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng\/ml. Urology 2007;69:103\u20137. doi:https:\/\/doi.org\/10.1016\/j.urology.2006.09.041","journal-title":"Urology"},{"key":"4717_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2147\/RRU.S117963","volume":"8","author":"S Al-Khalil","year":"2016","unstructured":"Al-Khalil S, Ibilibor C, Cammack JT, et al. Association of prostate volume with incidence and aggressiveness of prostate cancer. Res Rep Urol 2016;8:201\u2013205. doi:https:\/\/doi.org\/10.2147\/RRU.S117963","journal-title":"Res Rep Urol"},{"key":"4717_CR27","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/j.1464-410X.2011.10543.x","volume":"109","author":"NM Corcoran","year":"2012","unstructured":"Corcoran NM, Hovens CM, Hong MK, et al. Underestimation of gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU Int 2012;109:660\u20134. doi:https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10543.x","journal-title":"BJU Int"},{"key":"4717_CR28","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1159\/000100836","volume":"78","author":"JS Lee","year":"2007","unstructured":"Lee JS, Chung BH. Transrectal ultrasound versus magnetic resonance imaging in the estimation of prostate volume as compared with radical prostatectomy specimens. Urol Int 2007;78:323\u20137. doi:https:\/\/doi.org\/10.1159\/000100836","journal-title":"Urol Int"},{"key":"4717_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000144057","volume":"81","author":"CW Jeong","year":"2008","unstructured":"Jeong CW, Park HK, Hong SK, et al. Comparison of prostate volume measured by transrectal ultrasonography and mri with the actual prostate volume measured after radical prostatectomy. Urol Int 2008;81:179\u201385. doi:https:\/\/doi.org\/10.1159\/000144057","journal-title":"Urol Int"},{"key":"4717_CR30","doi-asserted-by":"publisher","first-page":"e200024","DOI":"10.1148\/rycan.2021200024","volume":"3","author":"M Bardis","year":"2021","unstructured":"Bardis M, Houshyar R, Chantaduly C, et al. Segmentation of the prostate transition zone and peripheral zone on mr images with deep learning. Radiol Imaging Cancer 2021;3:e200024. doi:https:\/\/doi.org\/10.1148\/rycan.2021200024","journal-title":"Radiol Imaging Cancer"},{"key":"4717_CR31","first-page":"41","volume":"157","author":"P Iversen","year":"1994","unstructured":"Iversen P, Rasmussen F, Christensen IJ. Serum testosterone as a prognostic factor in patients with advanced prostatic carcinoma. Scand J Urol Nephrol Suppl 1994;157:41\u20137.","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"4717_CR32","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0022-5347(01)62922-7","volume":"160","author":"LR Miller","year":"1998","unstructured":"Miller LR, Partin AW, Chan DW, et al. Influence of radical prostatectomy on serum hormone levels. J Urol 1998;160:449\u201353.","journal-title":"J Urol"},{"key":"4717_CR33","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1177\/1756287215597633","volume":"7","author":"JE Michaud","year":"2015","unstructured":"Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: An evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol 2015;7:378\u201387. doi:https:\/\/doi.org\/10.1177\/1756287215597633","journal-title":"Ther Adv Urol"},{"key":"4717_CR34","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1464-410X.2009.08378.x","volume":"104","author":"J Morote","year":"2009","unstructured":"Morote J, Ramirez C, G\u00f3mez E, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009;104:486\u20139. doi:https:\/\/doi.org\/10.1111\/j.1464-410X.2009.08378.x","journal-title":"BJU Int"},{"key":"4717_CR35","doi-asserted-by":"publisher","unstructured":"Lorenzo G, Ahmed SR, Hormuth II DA, et al. Patient-specific, mechanistic models of tumor growth incorporating artificial intelligence and big data. Annual Review of Biomedical Engineering 2023; 26. doi:https:\/\/doi.org\/10.1073\/pnas.1815735116","DOI":"10.1073\/pnas.1815735116"},{"key":"4717_CR36","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.1038\/s41388-019-0925-0","volume":"38","author":"W Huang","year":"2019","unstructured":"Huang W, Hu H, Zhang Q, et al. Regulatory networks in mechanotransduction reveal key genes in promoting cancer cell stemness and proliferation. Oncogene 2019;38:6818\u20136834. doi:https:\/\/doi.org\/10.1038\/s41388-019-0925-0","journal-title":"Oncogene"},{"key":"4717_CR37","doi-asserted-by":"publisher","unstructured":"Furler RL, Nixon DF, Brantner CA, et al. Tgf-\u03b2 sustains tumor progression through biochemical and mechanical signal transduction. Cancers (Basel) 2018;10. doi:https:\/\/doi.org\/10.3390\/cancers10060199","DOI":"10.3390\/cancers10060199"},{"key":"4717_CR38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/ncb2756","volume":"15","author":"F Calvo","year":"2013","unstructured":"Calvo F, Ege N, Grande-Garcia A, et al. Mechanotransduction and yap-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013;15:637\u201346. doi:https:\/\/doi.org\/10.1038\/ncb2756","journal-title":"Nat Cell Biol"},{"key":"4717_CR39","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/nbt0897-778","volume":"15","author":"G Helmlinger","year":"1997","unstructured":"Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK. Solid stress inhibits the growth of multicellular tumor spheroids. Nature biotechnology 1997; 15:778\u2013783. doi:https:\/\/doi.org\/10.1038\/nbt0897-778","journal-title":"Nature biotechnology"},{"key":"4717_CR40","doi-asserted-by":"publisher","first-page":"e4632","DOI":"10.1371\/journal.pone.0004632","volume":"4","author":"G Cheng","year":"2009","unstructured":"Cheng G, Tse J, Jain RK, Munn LL. Micro-environmental mechanical stress controls tumor spheroid size and morphology by suppressing proliferation and inducing apoptosis in cancer cells. PLoS one 2009; 4:e4632. doi:https:\/\/doi.org\/10.1371\/journal.pone.0004632","journal-title":"PLoS one"},{"key":"4717_CR41","doi-asserted-by":"publisher","first-page":"055008","DOI":"10.1088\/1367-2630\/14\/5\/055008","volume":"14","author":"F Montel","year":"2012","unstructured":"Montel F, Delarue M, Elgeti J, Vignjevic D, Cappello G, Prost J. Isotropic stress reduces cell proliferation in tumor spheroids. New Journal of Physics 2012; 14:055008.","journal-title":"New Journal of Physics"},{"key":"4717_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/cells13010096","volume":"13","author":"CT Mierke","year":"2024","unstructured":"Mierke CT. Extracellular matrix cues regulate mechanosensing and mechanotransduction of cancer cells. Cells 2024; 13:96. doi:https:\/\/doi.org\/10.3390\/cells13010096","journal-title":"Cells"},{"key":"4717_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.radonc.2022.06.011","volume":"173","author":"C Onal","year":"2022","unstructured":"Onal C, Erbay G, Guler OC, et al. The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance image in patients with prostate cancer treated with definitive radiotherapy. Radiother Oncol 2022;173:285\u2013291. doi:https:\/\/doi.org\/10.1016\/j.radonc.2022.06.011","journal-title":"Radiother Oncol"},{"key":"4717_CR44","doi-asserted-by":"publisher","first-page":"109677","DOI":"10.1016\/j.radonc.2023.109677","volume":"184","author":"C Onal","year":"2023","unstructured":"Onal C, Erbay G, Oymak E, et al. The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients. Radiother Oncol 2023;184:109677. doi:https:\/\/doi.org\/10.1016\/j.radonc.2023.109677","journal-title":"Radiother Oncol"},{"key":"4717_CR45","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.acra.2021.09.012","volume":"29","author":"A Chatterjee","year":"2022","unstructured":"Chatterjee A, Turchan WT, Fan X, et al. Can pre-treatment quantitative multi-parametric mri predict the outcome of radiotherapy in patients with prostate cancer? Acad Radiol 2022;29:977\u2013985. doi:https:\/\/doi.org\/10.1016\/j.acra.2021.09.012","journal-title":"Acad Radiol"},{"key":"4717_CR46","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.urolonc.2019.12.015","volume":"38","author":"WT Turchan","year":"2020","unstructured":"Turchan WT, Kauffmann G, Patel P, et al. Pi-rads score is associated with biochemical control and distant metastasis in men with intermediate-risk and high-risk prostate cancer treated with radiation therapy. Urol Oncol 2020;38:600.e1-600.e8. doi:10.1016\/j.urolonc.2019.12.015","journal-title":"Urol Oncol"},{"key":"4717_CR47","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.euo.2022.02.005","volume":"6","author":"D Gorovets","year":"2023","unstructured":"Gorovets D, Wibmer AG, Moore A, et al. Local failure after prostate sbrt predominantly occurs in the pi-rads 4 or 5 dominant intraprostatic lesion. Eur Urol Oncol 2023;6:275\u2013281. doi:https:\/\/doi.org\/10.1016\/j.euo.2022.02.005","journal-title":"Eur Urol Oncol"},{"key":"4717_CR48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.urolonc.2018.07.004","volume":"36","author":"G Kauffmann","year":"2018","unstructured":"Kauffmann G, Arif F, Patel P, et al. Pretreatment multiparametric mri is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol 2018;36:471.e11-471.e18. doi:10.1016\/j.urolonc.2018.07.004","journal-title":"Urol Oncol"},{"key":"4717_CR49","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s0090-4295(01)01233-x","volume":"58","author":"MW Kattan","year":"2001","unstructured":"Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001;58:393\u20139. doi:https:\/\/doi.org\/10.1016\/s0090-4295(01)01233-x","journal-title":"Urology"},{"key":"4717_CR50","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1200\/JCO.2000.18.19.3352","volume":"18","author":"MW Kattan","year":"2000","unstructured":"Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 2000;18:3352\u20139. doi:https:\/\/doi.org\/10.1200\/JCO.2000.18.19.3352","journal-title":"J Clin Oncol"},{"key":"4717_CR51","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijrobp.2009.03.031","volume":"76","author":"L Potters","year":"2010","unstructured":"Potters L, Roach M, Davis BJ, et al. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys 2010;76:1061\u20135. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2009.03.031","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4717_CR52","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.urology.2007.03.060","volume":"70","author":"MJ Zelefsky","year":"2007","unstructured":"Zelefsky MJ, Kattan MW, Fearn P, et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology 2007;70:283\u20137. doi:https:\/\/doi.org\/10.1016\/j.urology.2007.03.060","journal-title":"Urology"},{"key":"4717_CR53","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1148\/radiol.2382041905","volume":"238","author":"L Wang","year":"2006","unstructured":"Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: Incremental value of mr imaging and mr spectroscopic imaging to staging nomograms. Radiology 2006;238:597\u2013603. doi:https:\/\/doi.org\/10.1148\/radiol.2382041905","journal-title":"Radiology"},{"key":"4717_CR54","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.acra.2023.09.004","volume":"31","author":"J Lee","year":"2023","unstructured":"Lee J, Nandalur S, Hazy A, et al. Prostatic urethral length on mri potentially predicts late genitourinary toxicity after prostate cancer radiation. Acad Radiol 2023; 31:1950\u20131958. doi:https:\/\/doi.org\/10.1016\/j.acra.2023.09.004","journal-title":"Acad Radiol"},{"key":"4717_CR55","doi-asserted-by":"publisher","unstructured":"Nandalur KR, Shen C, Zhao L, Al-Katib S, Lee J, Seifman B, Ye H, Ginsburg K, Quinn T, Nandalur S, George A, Gangwish D, Dhaliwal A, Erwin C, Young A, Albeer A, Hafron J. Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC). J Urol. 2024 2024;212(4):571-9. doi:https:\/\/doi.org\/10.1097\/JU.0000000000004117.","DOI":"10.1097\/JU.0000000000004117"},{"key":"4717_CR56","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1200\/JCO.23.00617","volume":"41","author":"S Roy","year":"2023","unstructured":"Roy S, Romero T, Michalski JM, et al. Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate. J Clin Oncol 2023;41:5005\u20135014. doi:https:\/\/doi.org\/10.1200\/JCO.23.00617","journal-title":"J Clin Oncol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04717-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-024-04717-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-024-04717-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T20:03:55Z","timestamp":1747080235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-024-04717-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":56,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["4717"],"URL":"https:\/\/doi.org\/10.1007\/s00261-024-04717-7","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}